GlassScriptPhysician profile
Diego Martinez Nadramia
NPI 1639847460
$4,246.91
in general payments reported to CMS, 2019-2025
23 companies · $2,140 in 2025
The $2,140 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $617 · 2023: $860 · 2024: $511 · 2025: $2,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,061 · Travel and Lodging: $393 · Education: $56.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,060.91 |
| Travel and Lodging | $392.50 |
| Education | $56.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,058.27 | 2021-2025 | |
| Inspire Medical Systems, INC. | $758.66 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $545.79 | 2022-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $488.39 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $299.17 | 2022-2025 | Cuvitru, Takhzyro |
| Lundbeck LLC | $156.76 | 2023-2025 | Vyepti |
| Alk-Abello, INC | $142.40 | 2021-2023 | Grastek, Ragwitek, Odactra |
| Pfizer INC. | $111.06 | 2024-2025 | |
| Greer Laboratories, INC. | $109.43 | 2023-2025 | Oralair |
| Biocryst US Sales Co., LLC | $102.03 | 2024-2025 | Orladeyo |
| Abbvie INC. | $100.30 | 2021-2025 | |
| Aerin Medical INC. | $69.37 | 2024 | |
| Sanofi-Aventis U.S. LLC | $56.99 | 2025 | |
| Genentech USA, INC. | $56.73 | 2022-2025 | Xolair |
| Merck Sharp & Dohme LLC | $32.99 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $29.57 | 2025 | Neffy |
| Stryker Corporation | $21.12 | 2022 | |
| Ethicon US, LLC | $20.16 | 2022 | |
| Watermark Medical, INC. | $20.14 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $18.54 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $18.04 | 2022 | |
| Hikma Pharmaceuticals USA | $16.65 | 2022 | |
| Olympus America INC. | $14.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Martinez Nadramia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.